Hao, C., Shi, J., Song, Y., Ma, J., Yang, H., Jia, Y., Song, C., Meng, W., Zhang, J. (2025). Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase Ⅱ trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e13060